Medscape4d
‘Take a Photograph’: Trial Shows Big Survival Gain in Advanced EGFR-Mutant NSCLC
Final overall survival results show amivantamab plus lazertinib beat out osimertinib for first-line treatment of advanced ...
Healio5d
First-line combination should be ‘new standard’ in advanced lung cancer
The first-line combination of amivantamab-vmjw plus lazertinib extended OS compared with osimertinib for patients with EGFR-mutated advanced non-small cell lung cancer, according to data from the ...
Yahoo Finance6d
New study results reinforce TAGRISSO® (osimertinib) as the backbone therapy for EGFR-mutated lung cancer across stages and settings
together reinforce osimertinib as an effective, safe and convenient treatment for patients with EGFR-mutated lung cancer across stages and lines of treatment." Susan Galbraith, Executive Vice ...
National Institute for Health and Care Excellence1mon
Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection
There is a commercial access agreement for osimertinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
Business Insider India5y
Beware of cheap cancer drugs, they could be fakes from Bangladesh
Osimertinib by AstraZeneca which costs around ₹2 lakhs per dose can be bought for ₹4,500 per dose in the grey market. As many as 100-120 patients are consuming copies of Osimertinib/Afatinib.
Morningstar6d
New study results reinforce TAGRISSO® (osimertinib) as the backbone therapy for EGFR-mutated lung cancer across stages and settings
demonstrate the role of AstraZeneca’s TAGRISSO® (osimertinib), as monotherapy and as the backbone for novel combinations, across stages and settings of epidermal growth factor receptor-mutated ...
AstraZeneca: New study results reinforce TAGRISSO (osimertinib) as the backbone therapy for EGFR-mutated lung cancer across stages and settings
In LAURA Phase III trial, TAGRISSO continues to demonstrate improved overall survival trend in unresectable, Stage III setting SAVANNAH and ORCHARD Phase II trials show the addition of savolitinib ...